Aprea Therapeutics, Inc. (APRE) Stock Forecast
APRE analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $3.30 average of analyst targets
- Upside to target
- +465.1% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.08
- 52-week range
- $0.56 – $1.65
APRE analyst ratings
4 analystsNumber of analysts at each rating.
APRE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
APRE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.09 | −$0.07 | −$0.47 | +82.3% | 3 |
| Current fiscal year (2026) | −$0.36 | −$0.40 | −$0.28 | −$1.93 | +81.5% | 3 |
| Next fiscal year (2027) | −$0.40 | −$0.53 | −$0.33 | −$0.36 | −13.1% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
APRE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | −100.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 4 |
APRE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
APRE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.07 | −$0.08 | −$0.08 | −$0.08 | −63.8% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.83 | −$0.31 | −$0.34 | −$0.34 | −$0.36 | −57.0% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.79 | −$0.29 | −$0.34 | −$0.34 | −$0.40 | −48.9% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
APRE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; APRE beat in 10 of 12.
What analysts expect from APRE
4 analysts cover Aprea Therapeutics; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.30, 465.1% above the latest close of $0.58. Analysts expect earnings of −$0.36 per share for 2026, +81.5% from a year earlier. For 2027 the average estimate is −$0.40 per share. Aprea Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: APRE income statement, APRE key metrics, APRE chart. See the APRE stock overview for the latest quote and news.
APRE forecast FAQ
What is Aprea Therapeutics's price target?
The average analyst price target for Aprea Therapeutics is $3.30, 465.1% above the latest close of $0.58.
Is Aprea Therapeutics a buy, hold or sell?
Of 4 analysts covering Aprea Therapeutics, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Aprea Therapeutics's EPS forecast?
Analysts forecast −$0.36 per share for 2026 (range −$0.40 to −$0.28); for 2027 the estimate is −$0.40.
When does Aprea Therapeutics report earnings?
Aprea Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.08.
Does Aprea Therapeutics usually beat earnings estimates?
Aprea Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.